Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats

V. Čertíková Chábová, A. Walkowska, E. Kompanowska-Jezierska, J. Sadowski, P. Kujal, Z. Vernerová, Z. Vaňourková, L. Kopkan, H.J. Kramer, J.R. Falck, J.D. Imig, B.D. Hammock, I. Vaněčková, L. Červenka

. 2010 ; 118 (10) : 617-632. [pub] 20100223

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12025323

Grant support
NS9699 MZ0 CEP Register
NS10500 MZ0 CEP Register
NS10499 MZ0 CEP Register

Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12025323
003      
CZ-PrNML
005      
20141013124258.0
007      
ta
008      
120816e20100223enk f 000 0#eng||
009      
AR
024    7_
$a 10.1042/cs20090459 $2 doi
035    __
$a (PubMed)20050826
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Čertíková-Chábová, Věra $7 xx0095872 $u Department of Nephrology, 1st Medical Faculty, Charles University, Prague, Czech Republic; Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats / $c V. Čertíková Chábová, A. Walkowska, E. Kompanowska-Jezierska, J. Sadowski, P. Kujal, Z. Vernerová, Z. Vaňourková, L. Kopkan, H.J. Kramer, J.R. Falck, J.D. Imig, B.D. Hammock, I. Vaněčková, L. Červenka
520    9_
$a Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.
650    _2
$a kyselina 8,11,14-eikosatrienová $x analogy a deriváty $x metabolismus $7 D015126
650    _2
$a amidy $x farmakologie $x terapeutické užití $7 D000577
650    _2
$a angiotensin II $x farmakologie $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a preklinické hodnocení léčiv $x metody $7 D004353
650    _2
$a kyseliny hydroxyeikosatetraenové $x biosyntéza $7 D006893
650    _2
$a hypertenze $x komplikace $x farmakoterapie $x patofyziologie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multiorgánové selhání $x etiologie $x prevence a kontrola $7 D009102
650    _2
$a noradrenalin $x farmakologie $7 D009638
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renální oběh $x účinky léků $7 D012079
650    _2
$a sulfony $x farmakologie $x terapeutické užití $7 D013450
650    _2
$a vazokonstriktory $x farmakologie $7 D014662
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Walkowska, Agnieszka $u Laboratory of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Laboratory of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland
700    1_
$a Sadowski, Janusz $u Laboratory of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland
700    1#
$a Kujal, Petr. $7 xx0244311 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vaňourková, Zdeňka, $d 1973- $7 xx0074217 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Kopkan, Libor $7 xx0107287 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Kramer, Herbert J. $7 xx0085908 $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany
700    1_
$a Falck, John R $u Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 606-538, U.S.A.
700    1_
$a Imig, John D $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, U.S.A.
700    1_
$a Hammock, Bruce D $u Department of Entomology, University of California at Davis Cancer Center, Davis, CA 95616, U.S.A.
700    1_
$a Vaněčková, Ivana, $d 1964- $7 xx0030586 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105 $u Department for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
773    0_
$w MED00009494 $t Clinical science (London, England : 1979) $x 1470-8736 $g Roč. 118, č. 10 (20100223), s. 617-632
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20050826 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20141013124648 $b ABA008
999    __
$a ok $b bmc $g 947365 $s 782669
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 118 $c 10 $d 617-632 $e 20100223 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494
GRA    __
$a NS9699 $p MZ0
GRA    __
$a NS10500 $p MZ0
GRA    __
$a NS10499 $p MZ0
LZP    __
$a Pubmed-20120816/10/02

Find record

Citation metrics

Archiving options